Novel Pharmacological Strategies in the Treatment and Prevention of Acute Ischemic Stroke

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 3049

Special Issue Editors


E-Mail Website
Guest Editor
Department of Medical and Molecular Sciences, Università Politecnica delle Marche, 60126, Ancona, Italy
Interests: critical care medicine; internal medicine; clinical prediction; machine learning and big data analysis; atherosclerosis; Alzheimer's disease; atrial fibrillation; pulmonary embolism; ultrasounds in critical care
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Neurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona, Italy
Interests: stroke; cognitive impairment; dementia; carotid ultrasound; migraine; headache
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In recent years, treatment of acute ischemic stroke has seen a significant improvement thanks to both pharmacological and technological developments. Patients benefited greatly from an overall improvement in preventive strategies with newer anti-hypertensive and lipid-lowering drugs, direct oral anticoagulants, and more effective antiplatelet regimens that reduced the number of severe ischemic strokes. Moreover, newer combined strategies, such as fibrinolysis with sequential thrombectomy performed by better defining damaged areas with perfusion CT scan or MRI, resulted in overall improved functional outcomes.

In this Special Issue, we are interested in basic and translational research papers regarding the physiological, molecular, and clinical effects of newer pharmacological approaches in the context of preventive strategies or treatment of acute ischemic stroke. Both original articles and review papers will be considered for publication in this Special Issue of Biomedicines.

Dr. Lorenzo Falsetti
Dr. Giovanna Viticchi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

9 pages, 1657 KiB  
Article
In Vitro Blood Clot Formation and Dissolution for Testing New Stroke-Treatment Devices
by Kayla Wood, Sam E. Stephens, Feng Xu, Alshaimaa Hazaa, James C. Meek, Hanna K. Jensen, Morten O. Jensen and Ranil Wickramasinghe
Biomedicines 2022, 10(8), 1870; https://doi.org/10.3390/biomedicines10081870 - 03 Aug 2022
Cited by 4 | Viewed by 2554
Abstract
Strokes are among the leading causes of death worldwide. Ischemic stroke, due to plaque or other buildup blocking blood flow to the brain, is the most common type. Although ischemic stroke is treatable, current methods have severe shortcomings with high mortality rates. Clot [...] Read more.
Strokes are among the leading causes of death worldwide. Ischemic stroke, due to plaque or other buildup blocking blood flow to the brain, is the most common type. Although ischemic stroke is treatable, current methods have severe shortcomings with high mortality rates. Clot retrieval devices, for example, can result in physically damaged vessels and death. This study aims to create blood clots that are representative of those found in vivo and demonstrate a new method of removing them. Static blood clots were formed using a 9:1 ratio of whole sheep blood and 2.45% calcium chloride solution. This mixture was heated in a water bath at 37 °C for approximately one hour until solidified. Following clot solidification, human plasmin was introduced by various methods, including soaking, injection, and membrane perfusion, and the resulting dissolution percentages were determined. Different clot types, representative of the wide range found physiologically, were also manufactured and their dissolution characteristics evaluated. A method to reproducibly create blood clots, characteristic of those found in vivo, is essential for the production of stroke retrieval devices that can efficiently and effectively remove clots from patients with low mortality rates and little/no damage to the surrounding vessels. Full article
Show Figures

Figure 1

Back to TopTop